Pathogenesis of hypertrophic cardiomyopathy. Impact of growth factors on left ventricular anatomy

Minerva Cardioangiologica

Volumn 56, Issue 1, 2008, Pages 13-20

  Migliore, T ^a   Parrella, L S ^a   Caputi, A ^a   Silvestri, N ^a   Romano, R ^a   Pace, L ^a   Imbriaco, M ^a   Losi, M A ^a   Betocchi, S ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Dipartimento di Medicina Clinica Scienze Cardiovascolari ed Immunologiche   (Italy)

Author keywords

Cardiomyopathy, hypertrophic; Endomyocardial fibrosis; Transforming growth factors; Ventricular dysfunction, left

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; GELATINASE B; PROCOLLAGEN I AMINO TERMINAL PROPEPTIDE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; RADIOIMMUNOASSAY;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; COLLAGEN; ECHOCARDIOGRAPHY, DOPPLER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIUM; PEPTIDE FRAGMENTS; PROCOLLAGEN; RADIOIMMUNOASSAY; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 42049123650     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780-844.
2. Marian AJ, Roberts R. The Molecular Genetic Basis for Hypertrophic Cardiomyopathy. J Mol Cell Cardiol 2001;33;655-70.
3. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-64.
4. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355:58-60.
5. Watkins H, Seidman CE, Seidman JG, Feng HS, Sweeney HL. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy.Evidence of a dominant negative action. J Clin Invest 1996;98:2456-61.
6. Li G, Borger MA, Williams WG, Weisel RD; Mickle DAG; Wingle ED et al. Regional overexpression of insulin-like growth factor-I and transforming growth factor-beta1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 2002;123:89-95.
7. Ren J, Samson WK, Sowers JR. Insulin-like Growth Factor I as a Cardiac Hormone: Physiological and Pathophysiological Implications in Heart Disease. J Mol Cell Cardiol 1999;31:2049-61.
8. Li RK, Li G, Mickle DAG, Weisel RD, Merante F, Luss H et al. Overexpression of Transforming Growth Factor-β1 and Insulin-Like Growth Factor-I in Patients With Idiopathic Hypertrophic Cardiomyopathy. Circulation 1997;96:874-81.
9. Li Gi, Li RK, Mickle DAG, Weisel RD, Merante F, Ball WT et al. Elevated insulin-like growth factor-1 and transforming growth factor-1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy: A possible mechanism. Circulation 1998;98(Suppl 19):II144-9.
10. Saeki H, Hamada M, Hiwada K. Circulating Levels of Insulin Like Growth Factor-1 and Its Binding Proteins in Patients with Hypertrophic Cardiomyopathy. Circ J 2002;66:639-44.
11. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M et al. Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse model of Human Hypertrophic Cardiomyopathy. Circulation 2001;103:789-91.
12. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic Effects of Antioxidant N-Acetylcysteine in a Mouse Model of Human Hypertrophic Cardiomyopathy Mutation. J Am Coll Cardiol 2006;47:827-34.
13. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT et al. Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circ Res 2005;97:285-92.
14. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24.
15. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S et al. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy. Circulation 2004;109:1284-91.
16. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000;35:36-44.
17. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-82.
18. Briguori C, Betocchi S, Romano M, Manganelli F, Angela Losi M, Ciampi Q et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. Am J Cardiol 1999;84:309-15.
19. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M. Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy. Circulation 2003;108:1455-60.
20. Fassbach M, Schwartzkopff B. Elevated serum markers for collagen syntesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 2005;94:328-35.
21. Noji Y, Shimizu M, Ino H, Higashikata T, Yamaguchi M, Nohara A. Increased Circulating Matrix Metalloproteinase-2 in Patients With Hypertrophic Cardiomyopathy With Systolic Dysfunction. Circ J 2004;68:355-60.
22. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780-9.
23. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002;27:92-8.
24. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and left aortic valve replacement. Circulation 1989;79:744-55.